China Resources Pharmaceutical Group Ltd
HKEX:3320
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.51
6.99
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Income from Continuing Operations
China Resources Pharmaceutical Group Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Income from Continuing Operations
HK$13.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Income from Continuing Operations
HK$2.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Income from Continuing Operations
HK$1.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Income from Continuing Operations
ÂĄ2.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Income from Continuing Operations
ÂĄ4.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
12%
|
||
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Income from Continuing Operations
-$42.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
13.3B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Income from Continuing Operations amounts to 13.3B HKD.
What is China Resources Pharmaceutical Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
10%
Over the last year, the Income from Continuing Operations growth was 14%. The average annual Income from Continuing Operations growth rates for China Resources Pharmaceutical Group Ltd have been 32% over the past three years , 10% over the past five years .